(Cp-R)M(CO)(3)] (M= Re or Tc-99m) conjugates for theranostic receptor targeting by Can, Daniel et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
(Cp-R)M(CO)(3)] (M= Re or Tc-99m) conjugates for theranostic receptor
targeting
Can, Daniel; Schmutz, Paul; Sulieman, Samer; Spingler, Bernhard; Alberto, Roger
Abstract: Cyclopentadienyl complexes of 99mTc became accessible via a retro Diels-Alder synthetic ap-
proach of dimerized cyclopentadiene derivatives. So far, this approach was limited to derivatives compris-
ing a carboxylic acid group, directly conjugated to the Cp-ring, leading to complexes [(C5H5COOH)99mTc(CO)3]
and [(C5H5CONH-R)99mTc(CO)3], respectively. The introduction of an -NCO group via Curtius re-
arrangement and subsequent in situ reactions with alcohols or amines gave [(C5H5NHCO-OR)2] and
[(C5H5NHCO-NHR)2]. To increase the spacer lengths between the Cp-ring and the functional groups,
methylene and ethylene spacers were introduced to yield C5H5-CH2COOH and C5H5-C2H4COOH re-
spectively. The latter Cp-derivatives reacted with [99mTcO4)]- and in the presence of CO releasing/re-
ducing agents to the corresponding [(C5H5-spacer-COOH)99mTc(CO)3] complexes. The carboxylato
groups can be derivatized with targeting functions, leading to structurally altered receptor binding com-
plexes, with 99mTc for imaging and with rhenium for therapy. The nature of the 99mTc complexes was
assessed by HPLC comparison with the corresponding rhenium compounds.
DOI: 10.2533/chimia.2013.267
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-81852
Published Version
Originally published at:
Can, Daniel; Schmutz, Paul; Sulieman, Samer; Spingler, Bernhard; Alberto, Roger (2013). (Cp-R)M(CO)(3)]
(M= Re or Tc-99m) conjugates for theranostic receptor targeting. CHIMIA International Journal for
Chemistry, 67(4):267-270. DOI: 10.2533/chimia.2013.267
Laureates: awards and Honors, sCs FaLL Meeting 2012 CHIMIA 2013, 67, Nr. 4 267
doi:10.2533/chimia.2013.267 Chimia 67 (2013) 267–270 © Schweizerische Chemische Gesellschaft
*Correspondence: Prof. Dr. R. Alberto
University of Zürich
Institute of Inorganic Chemistry
Winterthurerstrasse 190
CH-8057 Zürich
Tel.: +41 44 635 46 31
E-mail: ariel@aci.uzh.ch
[(Cp-R)M(CO)
3
] (M= Re or
99m
Tc)
Conjugates for Theranostic Receptor
Targeting
Daniel Can
§
, Paul Schmutz, Samer Sulieman, Bernhard Spingler, and Roger Alberto*
§
SCS-DSM Award for best poster presentation
Abstract: Cyclopentadienyl complexes of
99m
Tc became accessible via a retro Diels-Alder synthetic approach of
dimerized cyclopentadiene derivatives. So far, this approach was limited to derivatives comprising a carboxylic
acid group, directly conjugated to the Cp-ring, leading to complexes [(C
5
H
5
COOH)
99m
Tc(CO)
3
] and [(C
5
H
5
CONH-
R)
99m
Tc(CO)
3
], respectively. The introduction of an –NCO group via Curtius rearrangement and subsequent in
situ reactions with alcohols or amines gave [(C
5
H
5
NHCO-OR)
2
] and [(C
5
H
5
NHCO-NHR)
2
]. To increase the spacer
lengths between the Cp-ring and the functional groups, methylene and ethylene spacers were introduced to yield
C
5
H
5
-CH
2
COOH and C
5
H
5
-C
2
H
4
COOH respectively. The latter Cp-derivatives reacted with [
99m
TcO
4
)]
-
and in the
presence of CO releasing/reducing agents to the corresponding [(C
5
H
5
-spacer-COOH)
99m
Tc(CO)
3
] complexes.
The carboxylato groups can be derivatized with targeting functions, leading to structurally altered receptor
binding complexes, with
99m
Tc for imaging and with rhenium for therapy. The nature of the
99m
Tc complexes was
assessed by HPLC comparison with the corresponding rhenium compounds.
Keywords: Bioorganometallic chemistry · Carbonic anhydrase inhibitors · Radiopharmaceuticals ·
Technetium · Theranostic
Introduction
Organometallic complexes with bioac-
tive ligands are of interest for noninvasive
imaging of biological events and therapeu-
tic treatment of diseases. While several d-
element cations are studied and used for
therapy,
99m
Tc is the most prominent in nu-
clear medical diagnostics. It would be de-
sirable in a theranostic sense (therapy and
diagnostics), to have identical homologous
compounds for combined therapy anddiag-
nosis.
[1–3]
Rhenium and technetium belong
to the same traid; therefore it is possible
to use respective congener compounds for
matched therapy and imaging.
[4–6]
While
Re-based compounds can be used for ther-
apy, the
99m
Tc homologs can serve as im-
aging agents for Single Photon Emission
Computed Tomography (SPECT).
[1,2,7]
[(CP-R)M(CO)
3
]-type compounds are
very stable under physiological condi-
tions and can synthetically be treated like
aromatic organic molecules. Focussing on
the synthesis of
99m
Tc-labelled radiophar-
maceuticals and the corresponding cold
rhenium compounds, a variety of organic
and inorganic cyclopentadienyl derivatives
has been synthesized and their complexes
biologically investigated.
Medicinal inorganic chemistry has pro-
gressed tremendously since the successful
introduction of Cisplatin in the late 1960s.
During the past 50 years, a multitude of
metal-containing anticancer, anti-inflam-
matory, antomicrobial, antimalarial and
antibacterial compounds, enzyme inhibi-
tors and MRI-contrast agents have been
exploited and investigated.
[8,9]
The vast
majority of clinically applied pharmaceu-
ticals are of organic nature. Many of the
organometallic or inorganic drug candi-
dates are believed to act in the same way
as Cisplatin whereas metal complexes
for structural recognition of receptors are
rarely found. Only recently, organometal-
lic compounds came into the scope of such
applications. The structural complexity of
metal-containing compounds that are sta-
ble in biological systems was recognized
to have an underestimated and unexplored
potential for medicinal applications.
[9–13]
Since nature has developed an enor-
mous realm of functionally and structur-
ally similar receptors and enzymes, selec-
tivity for a specific target is a key criterion
for the quality of an inhibitor.
[14]
Meggers
and coworkers showed recently that high
selectivity not only depends on intermo-
lecular interactions but also on a versatile
and directed three-dimensional arrange-
ment of different functionalities. As exem-
plified by organometallic protein kinase
inhibitors,
[15–17]
chemically inert organo-
metallic complexes offer the opportunity
to occupy biologically relevant chemical
space as compared to similar inhibitors
with a purely organic scaffold. Therefore,
bioorganometallic complexes exhibit high
potential as chemical probes.
[15,18–21]
The introduction of sterically demand-
ing metal complexes into small molecules
without affecting their biological activ-
ity is challenging. One possible strategy
was pioneered by Jaouen and coworkers.
In the late 1970s, Hanzlik et al. replaced
a phenyl ring in phenylalanine by ferro-
cene and observed that this organometallic
Cp
-
sandwich-complex was accepted as a
substrate in the binding pocket of phenyl-
alanine decarboxylase.
[22]
Based on this
observation, Jaouen developed a variety of
highly potent estrogen receptor inhibitors
by replacing a phenyl ring in Tamoxifen
with [(Cp-R)Re(CO)
3
]. The resulting mol-
ecules retained a high binding affinity for
the estrogen receptor.
[12,23–28]
Combining the observations made by
Meggers and by Jaouen, we studied the
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isocyanate reacted in situ with an alcohol
or an amine, to form 3a or 3b respectively.
With MeOH, the reaction was followed in
a time-resolved IR-experiment, evidencing
the successful transformation (Fig. 1).
Another motive in bioactive phar-
maceuticals is Ar-(CH
2
)
n
-CONHR.
Organometallic analogues of this moiety
could represent biomimetics for new phar-
maceuticals or imaging agents.
biological activity and the selectivity of
[(Cp-R)Re(CO)
3
]-complexes with differ-
ent targeting vectors. In order to follow the
theranostic concept, we prepared the cor-
responding
99m
Tc-complexes in water. For
future projects, we investigated different
Cp-building blocks comprising different
functional groups bound to the Cp-ring.
Results and Discussion
The derivatization of cyclopentadiene
(HCp) or its complexes has a long history
in organic and organometallic chemistry.
Many different substituents have been de-
scribed in literature.
[29–35]
However, reports
for coupling biologically active targeting
vectors are comparably scarce. Being part
of the spacer between the chelator and the
biovector, the functional group attached to
Cp is of great importance for a bifunctional
chelator (BFC).
We reported the unexpected forma-
tion of [(CpCOOH)
99m
Tc(CO)
3
] from
‘Thiele’s acid’, the Diels-Alder dimer of
HCp-COOH,
[36–38]
and subsequently a
general aqueous synthetic route to [(Cp-
R)
99m
Tc(CO)
3
]-type complexes was devel-
oped by derivatization of the acid function
via amide coupling to biotargeting vectors.
This procedure, where the carbonyl group
is assumed to play the important role of
a metal-anchoring group, allows a fully
aqueous preparation of a variety of bioac-
tive compounds.
[6,37,39]
Following this approach, we recently
reported organometallic carbonic anhy-
drase inhibitors (CAI) with superior selec-
tivity for the pharmaceutically relevant iso-
forms IX and XII.
[6]
One of the described
examples consisted of a [(CpNHCO-R)
Re(CO)
3
] building block derivatized with
an arylsulfonamide targeting vector and
showed the most pronounced selectivity
profile. The corresponding
99m
Tc-complex
however, has not yet been described, as
the required compound HCp-NH
2
is still
unknown.
Besides CAIs, many pharmacological
active species and natural substances are
aniline-based and contain the amino group
in the form of amides or as internal aryl-
sulfonamides. The replacement of such
motives by the organometallic congener
[(CpNHCO-R)M(CO)
3
] (M = Re or
99m
Tc)
would therefore increase application op-
portunities in therapy and in diagnosis.
Coupling of a hypothetical HCp-NH
2
to carboxylic acids would yield a carbonyl
group close to the HCp-ring. As shown
with ketones
[36]
and carboxylic acids,
[37]
the carbonyl group in α-position to the
HCp is an anchoring group, binding to
[
99m
Tc(OH
2
)
3
(CO)
3
]
+
and initializing the
retro Diels-Alder reaction and formation
of η
5
-coordinated Cp
–
-complexes. With
HCpNHCO-R, the carbonyl group would
be in the β-position, still close enough to
act as an anchoring group.
Aiming at the synthesis of HCp-NH
2
,
compounds 3a and 3b were synthesized
by Curtius rearrangement (Scheme 1). The
acid-azide 1 was obtained after treatment
of Thiele’s acid with diphenylphosphoryl
azide in toluene. Heating to 80 °C induced
the Curtius rearrangement. The resulting
Scheme 1. Synthetic
conditions: i) diphe-
nylphosphoryl azide
(DPPA), NEt
3
, toluene
80%; ii) heated to 80
°C, toluene; iii) ad-
dition of the nucleo-
philes a/b, toluene.
Scheme 2. Synthetic
conditions: i) bro-
moacetic acid, THF,
30–50%; ii) methyl-
3-brompropionate,
THF, 30–50%; iii)
LiOH, THF/MeOH/
H
2
O 69–74%.
Scheme 3. Synthetic
conditions: i)
Na
2
B
4
O
7
*10H
2
O
(Borax), H
2
O, 95 °C,
20%.
Fig. 1. Time-resolved
IR-measurement
of the Curtius rear-
rangement of 1 to 2
(complete after 20.52
min) and the following
nucleophilic addition
of MeOH (after 38.51
min) to form 3a.
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complexes. Since
99m
Tc complexes are
present in nanomol quantities only, com-
parison of retention times (radio- (
99m
Tc)
and UV/vis detection (Re) are the only
methods to assess the nature of
99m
Tc com-
pounds. Formation rates of the
99m
Tc prod-
ucts are different for ligands 5 (hydrolyzed
4) and 7 (hydrolyzed 6). With 5, formation
was quantitative after 30 min (Scheme
5) whereas the reaction with 7 gave only
7% product after the same time and 62%
after 5 h. Higher rates were achieved
when the labeling with 7 was performed
in a microwave reactor; at 130 °C and
30 min 65% product 12, 16% [
99m
TcO
4
]
–
and 19% [
99m
Tc(OH
2
)
3
(CO)
3
]
+
were ob-
tained (Scheme 6).
In order to prepare organometallic CAI
with
99m
Tc and based on 5 and 7,
[6]
com-
pounds 13 and 14 were prepared from 8
and 10b with rhenium. Compounds 13
and 14 extend our list of CAI, containing
a methylene spacer and an ethylene spacer
respectively between the carbonyl group
and the Cp-ring. These methylene groups
alter the distance between receptor binding
motive and pendent complex and will al-
low a more profound insight into SARs for
this important class of bioorganometallic
CA targeting agents (Scheme 7).
Conclusion
Derivatives of HCp comprising a CP-
NHCO-R spacer were prepared in their
dimeric form from Thiele’s acid by use of
the Curtius rearrangement. The reaction
progress was investigated by time-resolved
IR-measurement.Addition of nucleophiles
like alcohols or amines to isocyanate 2,
generated in situ the compounds 3a and 3b.
Compounds 5 and 7 contain a carboxyl-
ic acid function in β- or in γ-position, with
respect to the HCp-ring. Labelling experi-
ments with [
99m
Tc(OH
2
)
3
(CO)
3
]
+
proved
that these positions are still close enough
to allow anchoring of the metal center by
the carboxylic acid portion. Therefore,
bringing the metal in close proximity, η
5
-
coordination of the HCp-portion is sim-
plified. However, conversion rates of the
99m
Tc starting compounds were very differ-
ent for the ligand 5 compared to 7, which is
in accordance with the increasing distance
of the anchoring group to the HCp-moiety.
Compound 8 was synthesized in a similar
fashion to the
99m
Tc-compound 11 using
ligand 5 with [Re(Br)
3
(CO)
3
]
2–
in water,
As aforementioned, HCp-compounds
of the form C
5
H
5
-COOH can be labelled
as monomers or as dimers with
99m
Tc.
[36–38]
In the ligands 5 and 7 with an extended
spacer, this anchoring group is retained.
The carbonyl group is now in β- or in
γ-position relative to the HCp-ring, likely
still close enough to serve as an anchoring
group. Like Thiele’s acid, 5 and 7 can be
derivatized with bioactive functions.
Compounds 4 and 6 have both been
described before.
[30,40]
With bromoacetic
acid methylester or bromopropionic acid
methylester respectively, 4 and 6were syn-
thesized and basic hydrolysis gave 5 and 7
(Scheme 2).
The Re-complex 8 was synthesized
directly in water. Similar to
99m
Tc-labeling
of HCp-compounds, ligand 5 was reacted
with [ReBr
3
(CO)
3
]
2–
in water with Borax
(Na
2
B
4
O
7
*10H
2
O) at 95 °C, representing
one of the rare examples of an aqueous
synthesis of a complex [(CpR)Re(CO)
3
]
(Scheme 3). Yields were low (20%) due
to a competing cluster formation reaction
of [Re(OH
2
)
3
(CO)
3
]
+
under basic aqueous
conditions.
[41]
Complex 8 was analyzed by IR (KBr),
NMR (CDCl
3
), ESI-MS (CH
3
OH) and
elemental analysis. Crystals were grown
from CH
2
Cl
2
/hexane and the structure was
elucidated (Fig. 2).
Carboxylic acid complex 10b was not
accessible along the same route by us-
ing ligand 7. Instead, 10b was obtained
by Horner-Wardsworth-Emmons ole-
fination
[42]
of [(CpCOH)Re(CO)
3
].
[43]
Treatment with triethyl phosphonoacetate
in MeOH gave olefin 9 in 80% yield.
Hydrogenation of the double bond with
H
2
on Pd, followed by ester hydrolysis of
10a with LiOH gave the desired complex
10b (Scheme 4). Crystals were grown from
CH
2
Cl
2
/hexane and the expected structure
was confirmed (Fig. 3).
Compounds 5 and 7 were subjected to
labeling studies with
99m
Tc. Ligands were
present as monomers and in mM concen-
trations. The reactions were studied ‘all in
one’. The ligand and an Isolink Kit were
sealed in a vial and [
99m
TcO
4
]
–
was added.
Alternatively, a two-step procedure was
employed; [
99m
Tc(OH
2
)
3
(CO)
3
]
+
was syn-
thesized separately and added to the ligand.
Both procedures resulted in the clean for-
mation of the
99m
Tc-complexes 11 and 12
respectively (Scheme 5 and 6). No relevant
amounts of side products were observed in
either case. The products were analyzed
by coinjection with the corresponding Re
Scheme 4. Synthetic
conditions: i) triethyl
phosphonoacetate,
MeOH, 80%; ii) H
2
/
Pd/C, EtOAc (10a).
iii) LiOH, H
2
O/MeOH/
THF 98% (10b).
Scheme 5. Bottom-up trace: γ-trace of the
one-pot labeling of 5 with [
99m
TcO
4
]
–
and Isolink
Kit. Top-down trace: UV-trace of Re-compound
8. Quantitative and radiochemically pure con-
version of [
99m
TcO
4
]
–
to complex 11.
Fig. 2. ORTEP representation of 8. Relevant
bond lengths (Å): Re(1)–C(1) 1.912(2),
Re(1)–C(2) 1.917(2), Re(1)–C(3) 1.913(2),
Re(1)–C(7) 2.299(2), Re(1)–C(6) 2.3002(19),
Re(1)–C(5) 2.301(2), Re(1)–C(4) 2.3053(19),
Re(1)–C(8) 2.308(2).
Fig. 3. ORTEP representation of 10b. Relevant
bond lengths (Å) and angles (°): Re(1)–C(2)
1.910(3), Re(1)–C(3) 1.919(3), Re(1)–C(1)
1.919(3), Re(1)–C(6) 2.287(3), Re(1)–C(5)
2.291(3), Re(1)–C(7) 2.304(3), Re(1)–C(8)
2.311(3), Re(1)–C(4) 2.324(2), C(2)-Re(1)-C(1)
90.10(12), C(3)-Re(1)-C(1) 90.61(12).
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representing one of the rare examples of
an aqueous synthesis of a [(CpR)Re(CO)
3
]
complex. Compound 10b was prepared
using a Horner-Wardsworth-Emmons ole-
fination.
Compounds 13 and 14 extend our list
of CAI, containing a methylene spacer and
an ethylene spacer, respectively, between
the carbonyl group and the Cp-ring. These
groups alter the distance between receptor
binding motive and pendent complex and
will allow a more profound insight into
SARs for this important class of bioor-
ganometallic CA targeting agents.
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